Genomic profiling can identify actionable alterations

We now know that cancer is a disease of the genome.1 Studies indicate that 30% to 49% of patients who undergo tumor genomic profiling may have an actionable alteration, which means that patients may be able to be matched to either an approved or investigational therapy.2,3

genomic profiling

  • In 2 studies of genomic profiling in pediatric solid tumors, between 31% and 39% of patients had tumors with actionable alterations4,5
  • In a prospective clinical trial of 843 patients with advanced cancers, 49% of patients were found to have an actionable alteration through high-throughput genomic analysis3
  • In an analysis of 500 patients at MD Anderson with advanced cancer in multiple tumor types who had undergone genomic profiling, 30% were found to have actionable alterations2
 
References: 1. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014;5:4846. doi:10.1038/ncomms5846. 2. Boland GM, Piha-Paul SA, Subbiah V, et al. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015;6(24):20099-20110. 3. Massard C, Michiels S, Ferte C, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017;7(6):586-595. 4. Harris MH, DuBois SG, Glade Bender JL, et al. Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: the individualized cancer therapy (iCat) study. JAMA Oncol. 2016;2(5):608-615. 5. Parsons DW, Roy A, Yang Y, et al. Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol. 2016;2(5):616-624.

 

Bayer   loxo oncology© 2018 Bayer and Loxo Oncology, Inc. All rights reserved. Bayer and the Bayer Cross are registered trademarks of Bayer.